Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

BeiGene Approved to Launch Bi-Specific in China for Pediatric Leukemia Patients

publication date: May 4, 2022

BeiGene announced China approval for Blincyto® (blinatumomab) to treat pediatric patients with leukemia. In 2020, China’s NMPA approved Blincyto® for adult leukemia patients. BeiGene acquired rights to the candidate from Amgen as part of a $2.7 billion deal signed in 2019 that included China rights to 23 Amgen oncology drugs. BeiGene is responsible for developing the drugs in China (many of them pre-clinical), and Amgen acquired a 20% stake in BeiGene. In its latest approval, Blincyto® is indicated in China to treat pediatric patients with relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia. More details....

Stock Symbols: (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) (NSDQ: AMGN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital